Short Interest in Precipio, Inc. (NASDAQ:PRPO) Increases By 70.0%

Precipio, Inc. (NASDAQ:PRPO) saw a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 6,126 shares, an increase of 70.0% from the February 26th total of 3,604 shares. Based on an average daily trading volume, of 21,188 shares, the short-interest ratio is currently 0.3 days. Currently, 0.4% of the company’s stock are short sold.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precipio in a research report on Thursday, January 22nd. Wall Street Zen downgraded Precipio from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On Precipio

A number of institutional investors and hedge funds have recently modified their holdings of PRPO. AMH Equity Ltd lifted its stake in Precipio by 370.1% in the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock valued at $2,332,000 after purchasing an additional 103,210 shares during the last quarter. Topline Capital Management LLC acquired a new position in Precipio during the third quarter worth approximately $1,158,000. Evernest Financial Advisors LLC bought a new stake in Precipio in the third quarter valued at approximately $374,000. Geode Capital Management LLC raised its stake in Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 789 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Precipio by 10.7% in the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 1,400 shares during the last quarter. 10.45% of the stock is owned by institutional investors.

Precipio Stock Up 0.6%

PRPO traded up $0.17 during trading on Friday, reaching $26.71. 14,742 shares of the stock were exchanged, compared to its average volume of 17,663. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.10 and a current ratio of 1.27. The stock’s 50 day moving average price is $24.81 and its two-hundred day moving average price is $22.67. Precipio has a twelve month low of $3.90 and a twelve month high of $29.53. The stock has a market cap of $46.73 million, a P/E ratio of -32.57 and a beta of 1.22.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.